相似文献
1
Newly Developed Modified ALBI Grade Shows Better Prognostic and Predictive Value for Hepatocellular Carcinoma.
Liver Cancer. 2021 Dec 8;11(1):1-8. doi: 10.1159/000521374. eCollection 2022 Jan.
2
Clinical Utility of Albumin Bilirubin Grade as a Prognostic Marker in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: a Systematic Review and Meta-analysis.
J Gastrointest Cancer. 2023 Jun;54(2):420-432. doi: 10.1007/s12029-022-00832-0. Epub 2022 May 30.
3
Prognostic value of the albumin-bilirubin grade in patients with hepatocellular carcinoma: Validation in a Chinese cohort.
Hepatol Res. 2017 Jul;47(8):731-741. doi: 10.1111/hepr.12796. Epub 2016 Nov 3.
4
Modified CLIP score with the albumin-bilirubin grade retains prognostic value in HBV-related hepatocellular carcinoma patients treated with trans-catheter arterial chemoembolization therapy.
J Cancer. 2018 Jun 14;9(13):2380-2388. doi: 10.7150/jca.22925. eCollection 2018.
5
Prognostic value of the albumin-bilirubin grade in patients with hepatocellular carcinoma and other liver diseases.
Ann Transl Med. 2020 Apr;8(8):553. doi: 10.21037/atm.2020.02.116.
6
Comparison of Modified Child-pugh (MCP), Albumin-bilirubin (ALBI), and Child-pugh (CP) score for predicting of survival in Hepatocellular Carcinoma Patients Treated with Transcatheter Arterial Chemoembolization.
Bull Cancer. 2021 Oct;108(10):931-939. doi: 10.1016/j.bulcan.2021.04.017. Epub 2021 Jul 8.
7
Easy clinical predictor for low BCAA to tyrosine ratio in chronic liver disease patients with hepatocellular carcinoma: Usefulness of ALBI score as nutritional prognostic marker.
Cancer Med. 2021 Jun;10(11):3584-3592. doi: 10.1002/cam4.3908. Epub 2021 May 7.
8
Prognostic Value of Myosteatosis and Albumin-Bilirubin Grade for Survival in Hepatocellular Carcinoma Post Chemoembolization.
Cancers (Basel). 2024 Oct 17;16(20):3503. doi: 10.3390/cancers16203503.
9
Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis.
Liver Cancer. 2019 Mar;8(2):121-129. doi: 10.1159/000488778. Epub 2018 Jun 11.
10
A detailed assessment of liver function in patients with hepatocellular carcinoma via the modified albumin-bilirubin (mALBI) grade.
Am J Cancer Res. 2022 Jun 15;12(6):2711-2720. eCollection 2022.
引用本文的文献
1
Combination of modified albumin-bilirubin grade and platelet count to predict high-risk varices in patients with hepatocellular carcinoma.
PLoS One. 2025 Jul 17;20(7):e0327967. doi: 10.1371/journal.pone.0327967. eCollection 2025.
2
Chinese Expert Consensus on the Whole-Course Management of Hepatocellular Carcinoma (2023 Edition).
Liver Cancer. 2024 Oct 22;14(3):311-333. doi: 10.1159/000541622. eCollection 2025 Jun.
3
Systemic Therapy Combined with Locoregional Therapy in Intermediate-stage Hepatocellular Carcinoma.
Interv Radiol (Higashimatsuyama). 2024 Dec 13;10:e20230035. doi: 10.22575/interventionalradiology.2023-0035. eCollection 2025 Mar 28.
4
Prognostic impact of albumin-bilirubin score in predicting the long-term survival of distal cholangiocarcinoma after radical surgery.
World J Surg Oncol. 2025 Apr 24;23(1):160. doi: 10.1186/s12957-025-03813-2.
5
Incorporating ALBI Grade with Geriatric Nutritional Risk Index Enhances Hepatocellular Carcinoma Risk Stratification.
Liver Cancer. 2024 Oct 5;14(2):193-210. doi: 10.1159/000541647. eCollection 2025 Apr.
6
Predicting Mortality and Cirrhosis-Related Complications with MELD3.0: A Multicenter Cohort Analysis.
Gut Liver. 2025 May 15;19(3):427-437. doi: 10.5009/gnl240584. Epub 2025 Apr 11.
7
Lenvatinib plus Pembrolizumab Combined with Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma.
Liver Cancer. 2024 Dec 20;14(1):1-7. doi: 10.1159/000543245. eCollection 2025 Mar.
8
Validation of an albumin-indocyanine green-based China liver cancer staging system to evaluating resectable hepatocellular carcinoma patients and comparison with the Child-Pugh-based China liver cancer staging system.
Front Oncol. 2025 Feb 20;15:1450333. doi: 10.3389/fonc.2025.1450333. eCollection 2025.
9
Characterization and Detection Strategy Exploration in Cryptogenic Hepatocellular Carcinoma: Insights From a Super-Aged Region in Japan.
Cancer Med. 2025 Jan;14(2):e70490. doi: 10.1002/cam4.70490.
10
Construction of a random survival forest model based on a machine learning algorithm to predict early recurrence after hepatectomy for adult hepatocellular carcinoma.
BMC Cancer. 2024 Dec 25;24(1):1575. doi: 10.1186/s12885-024-13366-4.
本文引用的文献
1
Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study.
Sci Rep. 2021 Aug 17;11(1):16663. doi: 10.1038/s41598-021-96089-x.
2
Impact of modified albumin-bilirubin grade on survival in patients with HCC who received lenvatinib.
Sci Rep. 2021 Jul 14;11(1):14474. doi: 10.1038/s41598-021-93794-5.
3
Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update.
Liver Cancer. 2021 Jun;10(3):181-223. doi: 10.1159/000514174. Epub 2021 May 19.
4
The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study.
Cancers (Basel). 2021 May 26;13(11):2608. doi: 10.3390/cancers13112608.
5
EZ-ALBI Score for Predicting Hepatocellular Carcinoma Prognosis.
Liver Cancer. 2020 Dec;9(6):734-743. doi: 10.1159/000508971. Epub 2020 Oct 23.
6
Changes in Background Liver Function in Patients with Hepatocellular Carcinoma over 30 Years: Comparison of Child-Pugh Classification and Albumin Bilirubin Grade.
Liver Cancer. 2020 Sep;9(5):518-528. doi: 10.1159/000507933. Epub 2020 Jul 16.
7
Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib.
Oncology. 2020;98(11):787-797. doi: 10.1159/000509387. Epub 2020 Sep 3.
8
Early Relative Change in Hepatic Function with Lenvatinib for Unresectable Hepatocellular Carcinoma.
Oncology. 2019;97(6):334-340. doi: 10.1159/000502095. Epub 2019 Aug 29.
9
Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study.
Cancers (Basel). 2019 Jul 7;11(7):952. doi: 10.3390/cancers11070952.
10
Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis.
Liver Cancer. 2019 Mar;8(2):121-129. doi: 10.1159/000488778. Epub 2018 Jun 11.
Zotero 插件